72 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
8 Jan 24
Regulation FD Disclosure
10:29am
USE
Reblozyl: Significant growth opportunities in MDS-associated anemia and beyond Ongoing registrational studies 1L TD myelofibrosis(INDEPENDENCE
8-K
EX-1.1
BMY
Bristol-Myers Squibb Co.
13 Nov 23
Other Events
4:19pm
Investments, Inc.
PNC Capital Markets LLC
CAVU Securities, LLC
Drexel Hamilton, LLC
Independence Point Securities LLC
*We expect that delivery … Hamilton, LLC
Independence Point Securities LLC
Total
II-2
SCHEDULE III
Schedule III(a) Issuer Free Writing Prospectuses not included in the Pricing
424B5
o7fidh93iidqsgodm
1 Nov 23
Prospectus supplement for primary offering
4:16pm
FWP
kwr5 agfh2lq1rdrff2
30 Oct 23
Free writing prospectus
5:26pm
8-K
EX-99.2
vex00zza8ew 0tmf59
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.1
jx0maf jtd53up
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.2
mp2afz1fuk41oh
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
1t3c3
4 May 23
Departure of Directors or Certain Officers
4:48pm
8-K
EX-99.2
jwd0y0ieo0 gp
27 Apr 23
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
7:45am
DEFA14A
tseceud2szyzlnw
10 Apr 23
Additional proxy soliciting materials
5:12pm
8-K
EX-99.3
e3j0fnjd r3jauz
26 Oct 22
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
7:48am
8-K
EX-99.3
ep3e0prjrhf1fkkpd 21
27 Jul 22
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
7:44am
8-K
nltyd
15 Jun 22
Departure of Directors or Certain Officers
4:29pm
8-K
EX-99.3
v9yu ixsdusw0l
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
DEFA14A
l4chhin5wx 6z
20 Apr 22
Additional proxy soliciting materials
4:30pm
PX14A6G
1v68e ydzunt9b
5 Apr 22
Letter to shareholders
4:53pm